New Ways to Treat Advanced Prostate Cancer
Official title: Mechanisms of Androgen Receptor Inverse Agonists in Advanced Prostate Cancer
Funded at Case Western Reserve University · NIH-11133052 · Data updated 2026-11-12
This research looks for new ways to stop advanced prostate cancer from growing by changing how cancer cells respond to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 5, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $598,367 |
| NIH project number | 5R01CA291963-02 |
| Project ID | NIH-11133052 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is relevant for adult patients with advanced prostate cancer, especially those whose cancer has become resistant to hormone therapy.
✕Less likely to help
Patients whose prostate cancer is still responsive to standard hormone therapy may not directly benefit from this specific approach.
What this research studies
When prostate cancer becomes resistant to standard hormone therapy, it's called metastatic castration-resistant prostate cancer (mCRPC), which is much more aggressive. This project aims to understand how cancer cells become resistant by studying the "Androgen Receptor" and other proteins that drive tumor growth. Researchers are developing new molecules that can switch the Androgen Receptor's function, making it suppress the genes that normally help tumors grow. This work uses advanced lab models that closely mimic human tumors to find out how these new treatments work at a molecular level.
Why it matters
Potential benefit: If successful, this work could lead to entirely new treatments for advanced prostate cancer that overcome current drug resistance.
How similar studies have gone: This approach involves novel molecules and mechanisms, building on new evidence about how prostate cancer becomes resistant to treatment.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Gryder, Berkley E — Case Western Reserve University
- Study coordinator: Gryder, Berkley E
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.